ReviewFrontiers in immunology2026
Advancements and challenges in the management of chronic inducible urticaria.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic inducible urticaria (CIndU) is a group of diseases characterized by recurrent wheals and/or angioedema induced by specific triggers. Research into its underlying mechanisms remains underdeveloped, historically lagging behind that of chronic spontaneous urticaria (CSU). The profound heterogeneity across CIndU subtypes presents a central challenge, translating into limited and variable efficacy of conventional therapies, including second-generation H1-antihistamines and omalizumab, highlighting the inadequacy of a uniform management strategy. Encouragingly, the clinical development of novel targeted agents, notably anti-KIT biologics and Bruton's tyrosine kinase (BTK) inhibitors, now offers new promise. Concurrently, the refinement of disease-specific assessment tools and the exploration of biomarkers are facilitating a more personalized approach. This review summarizes recent advances and persistent challenges in CIndU management, advocating for a concerted effort to deepen mechanistic understanding, validate predictive biomarkers, and integrate patient stratification into future clinical trials, thereby paving the way for precision medicine in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.